The latest gynaecological cancer news
New Approach to Ovarian Cancer Treatment
Overall survival from ovarian cancer has not improved for several decades. Now, a Peter Mac-led…
Browsing: Gynaecologic Cancers
ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of…
ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy
In a small, phase II study of a very rare cancer that develops inside a…
Cervical precancer identified by fluorescence, in a step toward bedside detection
A team of researchers at Tufts University’s School of Engineering and its School of Medicine,…
Study confirms important clues to fight ovarian cancer
The rogue cellular engine that drives a majority of ovarian cancers remains frustratingly difficult to…
Personalised ovarian cancer risk prediction reduces worries
Offering personalised ovarian cancer risk prediction to women shows that 98 per cent of participants…
Funding to boost research into new therapy combinations for ovarian cancer
Peter Mac researchers have been awarded a four year grant from the Federal Government’s Medical…
ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation
Maintenance therapy with olaparib extended overall survival by nearly 13 months (12.9) compared with placebo…
FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
The Food and Drug Administration (FDA) expanded the indication of olaparib to include its combination…
FDA approves niraparib for first-line maintenance of advanced ovarian cancer
The Food and Drug Administration (FDA) approved niraparib for the maintenance treatment of adult patients…